Implementing evidence-based strategies for men with biochemically recurrent and advanced prostate cancer: Consensus recommendations from the US Prostate Cancer Conference 2024.

Autor: Bryce AH; Department of Medical Oncology and Therapeutics Research, City of Hope Phoenix, Phoenix, Arizona, USA., Agarwal N; Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah, USA., Beltran H; Department of Medical Oncology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA., Hussain MH; Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Evanston, Illinois, USA., Sartor O; Department of Medical Oncology, Mayo Clinic, Rochester, Minnesota, USA., Shore N; Carolina Urologic Research Center, Myrtle Beach, South Carolina, USA., Antonarakis ES; Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, USA., Armstrong AJ; Duke Cancer Institute Center for Prostate and Urologic Cancers, Durham, North Carolina, USA., Calais J; Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, University of California Los Angeles, Los Angeles, California, USA., Carducci MA; Hopkins Kimmel Cancer Center, Baltimore, Maryland, USA., Dorff TB; City of Hope Comprehensive Cancer Center, Duarte, California, USA., Efstathiou JA; Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA., Gleave M; Urological Sciences, Vancouver Prostate Center, University of British Columbia, Vancouver, British Columbia, Canada., Gomella LG; Department of Urology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania, USA., Higano C; Madrona Oncology, Seattle, Washington, USA., Hope TA; Department of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, California, USA., Iagaru A; Division of Nuclear Medicine and Molecular Imaging, Department of Radiology, Stanford University, Stanford, California, USA., Morgans AK; Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA., Morris DS; Urology Associates PC, Nashville, Tennessee, USA., Morris MJ; Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA., Petrylak DP; Yale New Haven Health, New Haven, Connecticut, USA., Reiter RE; Jonsson Comprehensive Cancer Center, University of California Los Angeles, Los Angeles, California, USA., Rettig MB; Division of Hematology-Oncology, Department of Medicine, VA Greater Los Angeles, Los Angeles, California, USA.; Department of Medicine, David Geffen School of Medicine at the University of California Los Angeles, Los Angeles, California, USA.; Department of Urology, David Geffen School of Medicine at the University of California Los Angeles, Los Angeles, California, USA., Ryan CJ; Department of Medicine, University of Minnesota, Minneapolis, Minnesota, USA., Sellinger SB; Advanced Urology Institute, Tallahassee, Florida, USA., Spratt DE; University Hospitals Seidman Cancer Center, Cleveland, Ohio, USA., Srinivas S; Division of Medical Oncology, Stanford University Medical Center, Stanford, California, USA., Tagawa ST; Division of Hematology and Medical Oncology, Weill Cornell Medicine, New York, New York, USA., Taplin ME; Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA., Yu EY; Division of Hematology and Oncology, Department of Medicine, University of Washington and Fred Hutchinson Cancer Center, Seattle, Washington, USA., Zhang T; Division of Hematology and Oncology, Department of Internal Medicine, Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, Texas, USA., McKay RR; Department of Urology, University of California San Diego, La Jolla, California, USA.; Department of Medicine, University of California San Diego, La Jolla, California, USA., Koo PJ; Banner MD Anderson Cancer Center, Phoenix, Arizona, USA., Crawford ED; Department of Urology, University of California San Diego, La Jolla, California, USA.
Jazyk: angličtina
Zdroj: Cancer [Cancer] 2024 Dec 01. Date of Electronic Publication: 2024 Dec 01.
DOI: 10.1002/cncr.35612
Abstrakt: Current US clinical practice guidelines for advanced prostate cancer management contain recommendations based on high-level evidence from randomized controlled trials; however, these guidelines do not address the nuanced clinical questions that are unanswered by prospective trials but nonetheless encountered in day-to-day practice. To address these practical questions, the 2024 US Prostate Cancer Conference (USPCC 2024) was created to generate US-focused expert clinical decision-making guidance for circumstances in which level 1 evidence is lacking. At the second annual USPCC meeting (USPCC 2024), a multidisciplinary panel of experts convened to discuss ongoing clinical challenges related to 5 topic areas: biochemical recurrence; metastatic, castration-resistant prostate cancer; poly [ADP-ribose] polymerase inhibitors; prostate-specific membrane antigen radioligand therapy; and metastatic, castration-resistant prostate cancer. Through a modified Delphi process, 34 consensus recommendations were developed and are intended to provide clinicians who manage prostate cancer with guidance related to the implementation of novel treatments and technologies. In this report, the authors review the areas of consensus identified by the USPCC 2024 experts and evaluate ongoing unmet needs regarding translational application of the current clinical evidence.
(© 2024 The Author(s). Cancer published by Wiley Periodicals LLC on behalf of American Cancer Society.)
Databáze: MEDLINE
Externí odkaz: